Shots:

• The interim data from 18 patients out of 20 in P-II trial evaluating the safety- tolerability- and efficacy of MS1819 (700/1200/2240 mg- qd- for 15 days/dosing level) + PERT aged 12 yrs or older in CF patients for EPI
• The 1EP & 2EP of the trial demonstrated improvement in CFA- improvement in stool weight- stool consistency- bowel movements- rate of steatorrhea & increased body weight- reduced the symptoms of EPI- improved QoL with safety profile. The results from all 20 patients enrolled in the trial are expected in Q2' 21
• The company expects to enrol ~24 CF patients with severe EPI and the study completion is expected in Q1’ 21

  Ref: GLOBE NEWSWIRE| Image: AzurRx BioPharma